LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Disease – First Step Toward Reimbursement

Contributed by: Business Wire

Logo

Tags

Medical Devices

Health

Clinical Trials

General Health

Optical

Biotechnology

LumiThera, Inc.

More Like This

LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda® Light Delivery System in Patients with Dry Age-Related Macular Degeneration (AMD)

LumiThera Provides Update on FDA Review of Valeda Treatment for Dry AMD Patients

LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision

PR Newswire associated0

Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa

PR Newswire associated0

THERAKOS™ CELLEX™ Photopheresis System Receives CE Certificate Under the European Union Medical Device Regulation (EU MDR)

MedLumics New CEO and Board Member Announces 10 Patients Treated in First in Man (FIM) Clinical Trial With the Real-Time Visually Guided AblaView PFA System

PR Newswire associated0

ViaLase Receives CE Mark for First Femtosecond Laser for the Treatment of Glaucoma, the ViaLase® Laser

PR Newswire associated0

Mallinckrodt Presents Data on Real-World Outcomes with THERAKOS™ CELLEX™ Photopheresis System Treatment at the 2024 Tandem Meetings